PRISMA-P Protocol Checklist: How to Write a Systematic Review Protocol That Meets Reporting Standards
PRISMA-P protocol checklist: all 17 items explained, PRISMA-P vs PRISMA 2020 comparison, protocol writing workflow, publication options, and common mistakes. Includes free PROSPERO formatter.
Building Your Search Strategy? We Can Run the Whole Review.
From protocol to PRISMA flow diagram, our PhD team handles database searches, screening, data extraction, and a publication-ready manuscript. Every step, done right.
Dr. Sarah Mitchell holds a PhD in Biostatistics from Johns Hopkins Bloomberg School of Public Health and has over 15 years of experience in systematic review methodology and meta-analysis. She has authored or co-authored 40+ peer-reviewed publications in journals including the Journal of Clinical Epidemiology, BMC Medical Research Methodology, and Research Synthesis Methods. A former Cochrane Review Group statistician and current editorial board member of Systematic Reviews, Dr. Mitchell has supervised 200+ evidence synthesis projects across clinical medicine, public health, and social sciences.
Building Your Search Strategy? We Can Run the Whole Review.
From protocol to PRISMA flow diagram, our PhD team handles database searches, screening, data extraction, and a publication-ready manuscript. Every step, done right.
Starting from $895. Final quote after we review your project.
Key elements: registration (PROSPERO), eligibility criteria, information sources, search strategy, study selection, data extraction, RoB approach, synthesis plan
The PRISMA-P protocol checklist is a 17-item reporting guideline designed to ensure that systematic review protocols are complete, transparent, and reproducible before the review begins. Published by Shamseer et al. (2015), PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) serves as the protocol-level counterpart to the PRISMA 2020 statement used for reporting completed systematic reviews (Page et al., 2021). If you are planning a systematic review, this checklist tells you exactly what to document and how to structure your protocol so that it meets the reporting standards expected by journals, funders, and registration platforms like PROSPERO.
A well-developed protocol is the foundation of a credible systematic review. It establishes the research question, defines eligibility criteria, pre-specifies the search strategy and synthesis methods, and identifies the tools you will use for risk of bias assessment. The PRISMA-P guidelines exist because protocols written without a structured framework tend to omit critical details, details that reviewers, editors, and peer evaluators will flag later. By following PRISMA-P from the start, you prevent post-hoc outcome switching, reduce the risk of bias in your own review process, and produce a document that is ready for PROSPERO registration or journal publication.
This guide walks through all 17 items, explains how PRISMA-P differs from PRISMA 2020, provides a practical workflow for writing your protocol, and identifies the most common mistakes researchers make when completing the checklist.
What Is the PRISMA-P Protocol Checklist?
PRISMA-P was developed to address a persistent problem in evidence synthesis: systematic review protocols were being written with inconsistent quality, missing key methodological details, and failing to provide the transparency needed for replication. The EQUATOR Network endorsed the guideline as the standard for protocol reporting in systematic reviews and meta-analyses.
The checklist was published in two companion papers, the checklist itself (Shamseer et al., 2015) and an explanation and elaboration document (Moher et al., 2015) that provides detailed guidance for each item. Together, these papers define what a complete systematic review protocol should contain.
PRISMA-P guides protocol development by structuring the document into three sections: Administrative Information (items 1-5), Introduction (items 6-7), and Methods (items 8-17). Each item corresponds to a specific element that the protocol must address. The checklist does not prescribe how to conduct the review, it prescribes what to report in the protocol so that readers can evaluate the planned methodology before data collection begins.
The relationship between PRISMA-P and the completed review is direct: PRISMA-P guides protocol development, and PRISMA 2020 guides the reporting of the finished review. A protocol written using PRISMA-P translates naturally into a PRISMA 2020-compliant report because the same methodological elements are addressed at both stages.
PRISMA-P vs PRISMA 2020, What Is the Difference?
PRISMA-P (protocol) vs PRISMA 2020 (final report). Source: Moher et al., 2015 BMJ; Page et al., 2021 BMJ.
Researchers frequently confuse these two guidelines, but they serve distinct purposes at different stages of the review lifecycle. Understanding the difference is essential for applying each one correctly.
PRISMA-P addresses what to plan and document before the review begins. It covers items specific to the planning phase: protocol registration details, amendment procedures, and the rationale for the review. The PRISMA-P checklist ensures that your pre-specified methods are documented transparently so that deviations during the review can be identified and justified.
PRISMA 2020 (Page et al., 2021) addresses what to report after the review is complete. It covers items specific to the reporting phase: search results, study selection outcomes, the PRISMA flow diagram, synthesis results, and certainty of evidence assessments. For a detailed walkthrough, see our PRISMA 2020 guidelines explained guide.
The two checklists are complementary, not interchangeable. Here is a comparison of their key differences:
Feature
PRISMA-P (Protocol)
PRISMA 2020 (Completed Review)
When to use
Before starting the review
When reporting the finished review
Number of items
17
27
Focus
What you plan to do
What you actually did
Registration
PROSPERO registration details
Registration number and protocol citation
Search strategy
Planned search strategy (draft)
Final executed search strategy
Results
Not applicable
Study selection, synthesis results
A systematic review follows PRISMA 2020 reporting guidelines in the final manuscript, but that manuscript is stronger when the underlying protocol was developed using PRISMA-P. The protocol serves as the benchmark against which the completed review is evaluated.
Need help with your systematic review?
Our team builds comprehensive search strategies, handles screening across databases, and delivers PRISMA 2020-compliant systematic reviews.
PRISMA-P 17 protocol items by section. Source: Moher et al., 2015, BMJ 349:g7647.
The 17 items in the PRISMA-P protocol checklist are organized into three sections. Each item requires specific information that must be documented in your protocol. The Cochrane Handbook (Higgins et al., 2023) provides additional methodological guidance for many of these elements.
Administrative Information (Items 1-5)
Item 1: Identification, Identify the protocol as a systematic review protocol in the title. Use terms like "protocol" and "systematic review" explicitly. A clear title ensures the document is indexed correctly in databases and registration platforms.
Item 2: Registration, Provide the registration number and registry name if the protocol has been registered. PROSPERO is the most widely used registry for systematic review protocols. If registration is pending, state this and provide the anticipated registry. For step-by-step guidance, see our our guide to prospero registration guide.
Item 3: Authors, List all protocol authors with their affiliations, contact details, and contributions. Specify the guarantor, the person responsible for the overall content of the protocol.
Item 4: Amendments, Describe the process for documenting any amendments to the protocol after registration. State where amendments will be recorded (e.g., PROSPERO update, published corrigendum, supplementary file with the final review).
Item 5: Support, Identify all sources of financial and non-financial support. Disclose the role of funders in the review process, including whether funders had any influence on the review question, methods, or interpretation.
Pro Tip
Name your tools explicitly
Don't write 'quality assessment.' Write 'RoB 2 for RCTs, ROBINS-I for cohort studies, Newcastle-Ottawa Scale for case-control studies.' Reviewers notice the difference.
Pro Tip
Write the protocol in PRISMA-P order
The 17 items flow logically. Following the sequence ensures completeness and makes reviewer checklist verification easy.
Pro Tip
Use our PROSPERO formatter after completing your PRISMA-P protocol
It extracts the registration fields directly from your protocol text.
Frequently Asked Questions
5
Not universally mandatory, but strongly recommended by Cochrane, JBI, and many journals. PROSPERO registration is free and widely expected.
17 items across 3 sections: Administrative Information (5), Introduction (2), and Methods (10).
Yes. PROSPERO captures registration details; PRISMA-P ensures your full protocol meets reporting standards. They are complementary.
Before screening begins. Ideally before running your search strategy. Protocol amendments after this point must be documented.
No. Use PRISMA-ScR for scoping review reporting. Scoping review protocols can use the JBI scoping review protocol template.
Item 6: Rationale, Describe the rationale for the review in the context of what is already known. Identify the gap in the existing evidence base that the review aims to address. Reference existing systematic reviews on the topic and explain why a new or updated review is needed.
Item 7: Objectives, Provide an explicit statement of the research question using a structured framework. The PICO framework structures research questions for intervention reviews (Population, Intervention, Comparator, Outcome). For qualitative or scoping reviews, use PCC (Population, Concept, Context) or another appropriate framework. State whether the review will address effectiveness, diagnostic accuracy, prognosis, or another question type.
Methods (Items 8-17)
Item 8: Eligibility criteria, Define the inclusion and exclusion criteria for studies. Specify the study designs to be included, the population characteristics, the intervention or exposure of interest, the comparator conditions, and the outcomes to be measured. Eligibility criteria must be specific enough that two independent reviewers would make the same inclusion decisions.
Item 9: Information sources, List all databases and sources to be searched, including gray literature sources, trial registries, and reference lists of included studies. Specify the date range for each source and any language restrictions. Name each database explicitly (e.g., MEDLINE via PubMed, Embase via Ovid, CINAHL via EBSCOhost).
Item 10: Search strategy, Present the full draft search strategy for at least one database. Include all search terms, Boolean operators, filters, and limits. The search strategy should be reproducible by an independent researcher using the same database.
Item 11: Study records, data management, Describe how records will be managed throughout the review. Specify the reference management software (e.g., EndNote, Zotero, Covidence) and how duplicates will be identified and removed.
Item 12: Study records, selection process, Describe the study selection process, including the number of reviewers who will screen titles, abstracts, and full texts. Specify how disagreements will be resolved (e.g., discussion, third reviewer, consensus). State whether a pilot screening exercise will be conducted.
Item 13: Study records, data collection process, Describe how data will be extracted from included studies. Specify whether a standardized data extraction form will be used, whether extraction will be performed independently by two reviewers, and how discrepancies will be resolved.
Item 14: Data items, List all variables for which data will be sought, including study characteristics, participant demographics, intervention details, outcome measures, and timing of assessments. Specify how missing data will be handled.
Item 15: Outcomes and prioritization, List the primary and secondary outcomes. Define each outcome including the metric, method of aggregation, and time points. Specify any outcome prioritization scheme.
Item 16: Risk of bias in individual studies, Describe the method for assessing risk of bias in included studies. Name the specific tools by study design: RoB 2 for randomized controlled trials, ROBINS-I for non-randomized studies of interventions, Newcastle-Ottawa Scale for observational studies, or other validated instruments. Specify who will conduct the assessments and how disagreements will be resolved. For practical guidance, see our online risk of bias assessment tool.
Item 17: Data synthesis, Describe the planned approach to data synthesis. For quantitative reviews, specify the meta-analysis model (fixed-effect or random-effects), the effect measure (risk ratio, odds ratio, mean difference, standardized mean difference), the software to be used, and the method for assessing statistical heterogeneity (e.g., I-squared, Cochran Q test). For qualitative synthesis, describe the narrative synthesis approach. Specify any planned subgroup analyses, sensitivity analyses, and meta-regression. State how publication bias will be assessed (e.g., funnel plot, Egger test).
Writing a systematic review protocol using the PRISMA-P checklist is most efficient when you follow the items in their numbered order. The 17 items flow logically from administrative setup through the research question to the full methods specification. Here is a practical workflow for completing each section.
Start with your research question. Frame it using the PICO framework for intervention reviews or PCC for scoping and qualitative reviews. The research question drives every subsequent decision, your eligibility criteria, search terms, outcome definitions, and synthesis approach all derive from it. Write the Objectives section (Item 7) first, even though it appears second in the checklist, because it anchors the entire protocol.
Define eligibility criteria precisely. Vague criteria like "adults with diabetes" are insufficient. Specify the population (e.g., adults aged 18 or older diagnosed with type 2 diabetes mellitus), the intervention (e.g., SGLT2 inhibitors at any dose), the comparator (e.g., placebo, active comparator, or standard care), and the outcomes (e.g., HbA1c reduction at 12 months or longer). Include the study designs you will accept (e.g., randomized controlled trials only, or randomized controlled trials and prospective cohort studies).
Build the search strategy with a librarian. Item 10 requires a full draft search strategy for at least one database. This is where many protocols fall short. Work with an information specialist or medical librarian to construct a comprehensive, reproducible search using controlled vocabulary (MeSH terms, Emtree terms) and free-text synonyms. Document every database you will search (Item 9), including gray literature sources and trial registries.
Name your risk of bias tools explicitly. Do not write "quality assessment will be performed." Instead, specify: "Risk of bias will be assessed using RoB 2 (Sterne et al., 2019) for randomized controlled trials and ROBINS-I (Sterne et al., 2016) for non-randomized studies." Reviewers and editors expect this level of specificity.
Pre-specify the synthesis plan. Describe exactly how you will synthesize the evidence. If you plan a meta-analysis, state the model (random-effects using the DerSimonian-Laird method or restricted maximum likelihood), the effect measure, and the heterogeneity assessment approach. If studies are too heterogeneous for meta-analysis, describe your narrative synthesis framework. Specify any planned subgroup analyses and their rationale, post-hoc subgroup analyses are a major source of bias, and pre-specifying them in the protocol prevents this.
Complete the administrative items. Fill in the title (Item 1), author details (Item 3), funding sources (Item 5), and amendment procedures (Item 4). Register the protocol on PROSPERO (Item 2), registration is free, and most journals now expect it. PROSPERO is the international prospective register of systematic reviews, and completing the registration form after your PRISMA-P protocol is written is straightforward because the form fields map directly to the checklist items. For help structuring the registration, use our online prospero registration formatter.
Review against the checklist. Before submitting the protocol for registration or publication, check every item systematically. Use the checklist as a verification tool, read each item, locate the corresponding content in your protocol, and note the page number. This is the same process that journal reviewers and editors will follow.
Where to Publish Your Systematic Review Protocol
Publishing or registering your protocol is a critical step that establishes priority, prevents duplication, and creates an accountability record. There are several options, and they are not mutually exclusive.
PROSPERO is the most widely used registration platform. It is free, maintained by the Centre for Reviews and Dissemination at the University of York, and accepted by virtually all journals. PROSPERO registration does not constitute publication, it is a registration record that provides a time-stamped, publicly accessible summary of your planned review. Most journals now require or strongly recommend PROSPERO registration for systematic reviews.
Systematic Reviews (BioMed Central) is a dedicated open-access journal that publishes systematic review protocols as peer-reviewed articles. Publishing your protocol here provides a citable reference, undergoes peer review that can improve the protocol before the review begins, and establishes priority in the academic record.
BMJ Open accepts systematic review protocols and provides a high-impact platform for health-related review protocols. The journal is open access and indexed in major databases.
JMIR Research Protocols publishes protocols across health research, including systematic reviews. It offers relatively fast peer review and open-access publication.
Other options include discipline-specific journals that accept protocols (e.g., Environmental Evidence, Campbell Systematic Reviews) and institutional repositories. Some researchers register on PROSPERO and publish the full protocol separately, maximizing both accessibility and academic credit.
Even experienced researchers make errors when completing the PRISMA-P checklist. These mistakes create problems during peer review, registration, and, most critically, during the review itself when ambiguities in the protocol force ad-hoc decisions.
Not naming specific tools. The most frequent error in Item 16 is writing "quality assessment will be performed using a validated tool" without naming the instrument. Specify the exact tool for each study design: RoB 2 for RCTs, ROBINS-I for non-randomized intervention studies, AMSTAR 2 for included systematic reviews, or whatever instruments are appropriate for your review. Vague language signals to reviewers that you have not yet decided, which undermines confidence in the entire protocol.
Vague eligibility criteria. Writing "studies about depression" as your population criterion is insufficient. Eligibility criteria must be specific enough that two independent reviewers would reach the same inclusion decision for any given study. Define the clinical condition with diagnostic criteria, specify the age range, and clarify whether you are including clinical, community, or both populations.
Not pre-specifying subgroup analyses. Subgroup analyses performed post-hoc, after seeing the data, are a well-documented source of bias in systematic reviews. The Cochrane Handbook (Higgins et al., 2023) emphasizes that subgroup analyses should be pre-specified in the protocol with a clear rationale. If you plan to examine treatment effects by age group, disease severity, or intervention dose, state this in the protocol under Item 17.
Registering without completing the checklist. Some researchers register on PROSPERO with incomplete details, intending to update later. This defeats the purpose of protocol registration. The registration should reflect a complete, well-considered protocol, not a placeholder. Complete your PRISMA-P checklist first, then register.
Not documenting the amendment process. Item 4 requires a description of how protocol amendments will be handled. Many researchers skip this item or write a single vague sentence. Specify where amendments will be recorded (PROSPERO update, supplementary appendix in the final review), what triggers an amendment (e.g., change in eligibility criteria, addition of databases, modification of synthesis approach), and how the amendment date and rationale will be documented.
Omitting gray literature sources. Item 9 requires a comprehensive list of information sources, not just the major databases. Failing to include gray literature sources (conference proceedings, theses, preprint servers, trial registries) introduces publication bias at the protocol level. Specify every source you plan to search, including OpenGrey, ProQuest Dissertations, ClinicalTrials.gov, and discipline-specific repositories.
Incomplete search strategy. Item 10 requires the full draft search strategy for at least one database, yet many protocols present only a list of keywords without Boolean operators, field tags, or controlled vocabulary terms. The search strategy must be reproducible, an independent researcher should be able to run the identical search and retrieve the same results.
A PRISMA-P protocol checklist completed with attention to these common pitfalls produces a protocol that withstands peer review scrutiny, facilitates PROSPERO registration, and, most importantly, provides a reliable roadmap for conducting the systematic review itself. The time invested in a thorough protocol pays dividends throughout the entire review process, from search execution through final manuscript reporting under PRISMA 2020.
Diagnostic test accuracy meta-analysis pools paired sensitivity and specificity estimates across studies using bivariate or HSROC models. This guide covers when bivariate methods are required, the role of the summary ROC curve, threshold effects, QUADAS-2 risk of bias, and software options including R mada, R metafor, and Stata midas.
Individual participant data meta-analysis pools raw participant-level data across studies instead of aggregate effect estimates. This guide covers when an IPD meta-analysis is justified, one-stage versus two-stage models, data acquisition and harmonization, software (Stata ipdmetan, R metafor and ipdma), reporting under PRISMA-IPD, and common pitfalls in subgroup and interaction testing.
Research Gold's medical translation service delivers publication-grade translations of manuscripts, clinical trial protocols, regulatory submissions, and patient-reported outcome instruments. Translators are PhD-credentialed and ATA-certified, working through a two-translator translation, edit, proofread workflow. English-Arabic is our deepest pair, with strong coverage of Spanish, Mandarin, French, German, Portuguese, Japanese, Korean, and Turkish. From $0.12 per source word.
